Glucotrack, Inc. (NASDAQ: GCTK) is focused on the design, development, and commercialization of novel technologies for people with diabetes. The Company is currently developing a long-term implantable ...

Glucotrack (GCTK) announced an agreement with OneTwo Analytics AB. Through this collaboration, Glucotrack will leverage next-generation ...

Glucotrack (Nasdaq:GCTK) announced that it expects FDA investigational device exemption for its long-term CBGM later this ...

Javascript is required for you to be able to read premium content. Please enable it in your browser settings.

Transformational 2024: successfully advanced from preclinical to clinical stage company Strengthened leadership team to drive growth and advance clinical development Investigational Device Exemption ...

Shares of Ouster, Inc. OUST rose sharply in today's pre-market trading after the company reported better-than-expected fourth-quarter financial results. Ouster reported quarterly losses of 48 ...

(RTTNews) - Glucotrack, Inc. (GCTK), Wednesday, announced the results from its first-in-human trial of its continuous blood glucose monitoring or CBGM system, which will be presented at the 2025 ...

DETROIT, MICHIGAN - March 19, 2025 (NEWMEDIAWIRE) - Paul Goode, President & CEO, GlucoTrack (NASDAQ: GCTK), was recently a guest on Benzinga’s All-Access. GlucoTrack is a medical technology ...

RUTHERFORD, N.J., March 19, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (GCTK), a medical device company focused on the design, development, and commercialization of novel technologies for people ...

Glucotrack, Inc. announced that it will present safety and performance data from its first-in-human trial of a long-term continuous blood glucose monitoring (CBGM) system at the 2025 International ...

Paul Goode, President & CEO, GlucoTrack GCTK, was recently a guest on Benzinga's All-Access. GlucoTrack is a medical technology company whose two-year implantable Continuous Blood Glucose ...